Provided by Tiger Trade Technology Pte. Ltd.

Recursion Pharmaceuticals, Inc.

4.68
+0.480011.43%
Post-market: 4.690.0101+0.22%17:49 EST
Volume:64.88M
Turnover:312.50M
Market Cap:2.43B
PE:-2.62
High:5.01
Open:4.51
Low:4.48
Close:4.20
52wk High:12.36
52wk Low:3.79
Shares:519.84M
Float Shares:415.00M
Volume Ratio:4.25
T/O Rate:15.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7839
EPS(LYR):-1.6909
ROE:-91.06%
ROA:-42.04%
PB:2.32
PE(LYR):-2.77

Loading ...

Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q3 $0.36 Loss a Share, vs. FactSet Est of $0.38 Loss

MT Newswires Live
·
Nov 05

Recursion Pharmaceuticals Q3 EPS $(0.36) Misses $(0.31) Estimate, Sales $5.175M Miss $16.983M Estimate

Benzinga
·
Nov 05

Stock Track | Recursion Pharmaceuticals Plunges 5% Pre-Market on Weak Q3 Results and CEO Transition

Stock Track
·
Nov 05

Stock Track | Recursion Pharmaceuticals Plunges 5% Pre-Market on Weak Q3 Results and CEO Transition

Stock Track
·
Nov 05

Recursion Pharmaceuticals reports $30 million milestone payment and $785 million cash balance for Q3 2025

Reuters
·
Nov 05

Recursion Pharmaceuticals Inc: Q3 Total Revenue $5.2 Mln

THOMSON REUTERS
·
Nov 05

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 05

Recursion Pharmaceuticals Names Najat Khan as CEO

Reuters
·
Nov 05

Recursion Pharmaceuticals Inc - Najat Khan to Succeed Chris Gibson as CEO

THOMSON REUTERS
·
Nov 05

Recursion Pharmaceuticals Inc - Chris Gibson to Become Chairman of the Board

THOMSON REUTERS
·
Nov 05

Press Release: Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Dow Jones
·
Nov 05

Recursion Pharmaceuticals to Participate in Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 04

Roche Exercises Option with Recursion Pharmaceuticals

TIPRANKS
·
Oct 29

Recursion Pharmaceuticals Inc - Announces Roche's Exercise of Option for Microglia Map - SEC Filing

THOMSON REUTERS
·
Oct 29

Recursion Pharmaceuticals Secures $30 Million Acceptance Fee From Roche for Microglia Map

Reuters
·
Oct 29

Recursion Pharmaceuticals (RXRX): Exploring Valuation as AI Expansion, Key Merger, and Clinical Progress Boost Interest

Simply Wall St.
·
Oct 28

Recursion Pharmaceuticals Inc. to Report Third Quarter 2025 Results

Reuters
·
Oct 28

Press Release: Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Dow Jones
·
Oct 28

Why Recursion Pharmaceuticals (RXRX) Is Down 9.6% After AI Merger With Exscientia and Pipeline Update

Simply Wall St.
·
Oct 27

Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares

Reuters
·
Oct 25